CLARITIN HIVES RELIEF Drug Patent Profile
✉ Email this page to a colleague
When do Claritin Hives Relief patents expire, and what generic alternatives are available?
Claritin Hives Relief is a drug marketed by Bayer Healthcare Llc and is included in three NDAs.
The generic ingredient in CLARITIN HIVES RELIEF is loratadine. There are thirty-nine drug master file entries for this compound. One hundred and fifty-five suppliers are listed for this compound. Additional details are available on the loratadine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Claritin Hives Relief
A generic version of CLARITIN HIVES RELIEF was approved as loratadine by PLD ACQUISITIONS LLC on January 21st, 2003.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CLARITIN HIVES RELIEF?
- What are the global sales for CLARITIN HIVES RELIEF?
- What is Average Wholesale Price for CLARITIN HIVES RELIEF?
Summary for CLARITIN HIVES RELIEF
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 3 |
Finished Product Suppliers / Packagers: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 148 |
Clinical Trials: | 27 |
Patent Applications: | 3,409 |
DailyMed Link: | CLARITIN HIVES RELIEF at DailyMed |
Recent Clinical Trials for CLARITIN HIVES RELIEF
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Andover Research Eye Institute | Phase 4 |
Rutgers, The State University of New Jersey | Early Phase 1 |
National Cancer Institute (NCI) | Early Phase 1 |
US Patents and Regulatory Information for CLARITIN HIVES RELIEF
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Healthcare Llc | CLARITIN HIVES RELIEF | loratadine | SYRUP;ORAL | 020641-003 | Nov 19, 2003 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Bayer Healthcare Llc | CLARITIN HIVES RELIEF | loratadine | TABLET;ORAL | 019658-003 | Nov 19, 2003 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Bayer Healthcare Llc | CLARITIN HIVES RELIEF REDITAB | loratadine | TABLET, ORALLY DISINTEGRATING;ORAL | 020704-003 | Nov 19, 2003 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CLARITIN HIVES RELIEF
See the table below for patents covering CLARITIN HIVES RELIEF around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Israel | 78771 | PROCESS FOR PREPARING DIHYDRO-DIBENZO(A,D)CYCLOHEPTENES AND AZADERIVATIVES THEREOF,CERTAIN SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ⤷ Sign Up |
Hong Kong | 75993 | PROCESS FOR PREPARING PIPERIDYLIDENE DIHYDRODIBENZO(A,D)CYCLOHEPTENES AND AZA DERIVATIVES THEREOF,COMPOUNDS OBTAINED BY SUCH PROCESS AND THE USE OF SUCH COMPOUNDS FOR PREPARING USEFUL PHARMACEUTICAL COMPOSITIONS | ⤷ Sign Up |
South Korea | 830006218 | ⤷ Sign Up | |
Japan | S5735586 | NOVEL ANTIHISTAMIC | ⤷ Sign Up |
El Salvador | 1999000068 | JARABE ANTIHISTAMINICO ESTABILIZADO | ⤷ Sign Up |
Australia | 543054 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CLARITIN HIVES RELIEF
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1110543 | SPC/GB08/005 | United Kingdom | ⤷ Sign Up | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022. |
0152897 | C00152897/01 | Switzerland | ⤷ Sign Up | FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH |
0152897 | SPC/GB01/012 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115 |
1110543 | 08C0004 | France | ⤷ Sign Up | PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730 |
0152897 | 2001C/013 | Belgium | ⤷ Sign Up | PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |